0001213900-22-008987.txt : 20220223
0001213900-22-008987.hdr.sgml : 20220223
20220223164532
ACCESSION NUMBER: 0001213900-22-008987
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220218
FILED AS OF DATE: 20220223
DATE AS OF CHANGE: 20220223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FEBBO WILLIAM J
CENTRAL INDEX KEY: 0001413987
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38543
FILM NUMBER: 22664588
MAIL ADDRESS:
STREET 1: 600 CALIFORNIA ST., 9TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OptimizeRx Corp
CENTRAL INDEX KEY: 0001448431
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389]
IRS NUMBER: 261265381
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 WATER ST., STE. 200
CITY: ROCHESTER
STATE: MI
ZIP: 48307
BUSINESS PHONE: 248-651-6558
MAIL ADDRESS:
STREET 1: 400 WATER ST., STE. 200
CITY: ROCHESTER
STATE: MI
ZIP: 48307
4
1
ownership.xml
X0306
4
2022-02-18
0
0001448431
OptimizeRx Corp
OPRX
0001413987
FEBBO WILLIAM J
C/O OPTIMIZERX CORPORATION
400 WATER STREET, SUITE 200
ROCHESTER
MI
48307
1
1
0
0
CHIEF EXECUTIVE OFFICER
Common Stock
2022-02-18
4
S
0
9200
43.379
D
453138
D
Common Stock
2022-02-18
4
S
0
7066
44.122
D
446072
D
Common Stock
2022-02-18
4
S
0
400
44.960
D
445672
D
The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.84 to $43.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.93 to $44.97. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.
/s/ William J. Febbo
2022-02-22